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The most potent known naturally occurring Bowman-
Birk inhibitor, sunflower trypsin inhibitor-1 (SFTI-1), is
a bicyclic 14-amino acid peptide from sunflower seeds
comprising one disulfide bond and a cyclic backbone. At
present, little is known about the cyclization mechanism
of SFTI-1. We show here that an acyclic permutant of
SFTI-1 open at its scissile bond, SFTI-1[6,5], also func-
tions as an inhibitor of trypsin and that it can be enzy-
matically backbone-cyclized by incubation with bovine
-trypsin. The resulting ratio of cyclic SFTI-1 to SFTI-
1[6,5] is 9:1 regardless of whether trypsin is incubated
with SFTI-1[6,5] or SFTI-1. Enzymatic resynthesis of the
scissile bond to form cyclic SFTI-1 is a novel mechanism
of cyclization of SFTI-1[6,5]. Such a reaction could po-
tentially occur on a trypsin affinity column as used in
the original isolation procedure of SFTI-1. We therefore
extracted SFTI-1 from sunflower seeds without a trypsin
purification step and confirmed that the backbone of
SFTI-1 is indeed naturally cyclic. Structural studies on
SFTI-1[6,5] revealed high heterogeneity, and multiple
species of SFTI-1[6,5] were identified. The main species
closely resembles the structure of cyclic SFTI-1 with the
broken binding loop able to rotate between a cis/trans
geometry of the I7–P8 bond with the cis conformer being
similar to the canonical binding loop conformation. The
non-reactive loop adopts a -hairpin structure as in cy-
clic wild-type SFTI-1. Another species exhibits an iso-
aspartate residue at position 14 and provides implica-
tions for possible in vivo cyclization mechanisms.
Over recent years there has been much interest in the dis-
covery of circular proteins in higher organisms (1) and in the
development in synthetic approaches to cyclize proteins (2). In
general, backbone cyclic peptides have several advantages over
their non-cyclic counterparts. They are resistant to attack by
exopeptidases, making them less vulnerable to degradation
and can have an increased thermal stability (3). Also, unfavor-
able entropic losses upon binding to target proteins are signif-
icantly reduced, resulting in a thermodynamically more effi-
cient binding interaction (1). These biological advantages of
backbone cyclized peptides may lead to their use as scaffolds for
the design of stable pharmaceuticals and pesticides (4).
The new generation of circular peptides/proteins discovered
in the last few years differs from previously known cyclic pep-
tides such as cyclosporins in that the latter are generally not
direct gene products but are synthesized in bacteria by multi-
functional enzymes and often contain non-conventional amino
acids (5). By contrast, recently discovered circular miniproteins
such as the plant cyclotides (6) are gene products that are
post-translationally processed to cyclize their conventional
peptide backbone (7). Although in vitro cyclization procedures
are now being developed for the synthetic production of circular
proteins, little is known about the mechanisms and driving
force behind in vivo cyclization of naturally occurring cyclic
proteins. This is in part because limited knowledge about the
locality of the NH2- and COOH termini of putative linear
precursors of cyclic proteins makes predictions about cycliza-
tion mechanisms difficult.
More than 50 naturally occurring backbone cyclized proteins
have now been reported (1), with three of these being proteinase
inhibitors: MCoTI-I and MCoTI-II from Momordica cochinchi-
nensis (8, 9), and SFTI-11 from sunflower seeds (10). The Bow-
man-Birk (BB) inhibitor SFTI-1, shown in Fig. 1, is the focus of
the current study and is the smallest known cyclic plant peptide.
It is the most potent and only known cyclic BB inhibitor, having
a Ki value for trypsin in the sub-nanomolar range (10–14).
Interestingly, the cyclic backbone of SFTI-1 does not appear
to be essential for the high potency, because we recently
showed that SFTI-1[1,14], an acyclic permutant of SFTI-1, with
a break in the backbone chain between residues 1 and 14 (see
Fig. 1), also has a very high affinity for trypsin (11). Although
its Ki value is apparently about 20-fold weaker than the cyclic
form, this difference is not highly significant due to the diffi-
culties of accurately determining Ki values for such potent
inhibitors (15). Zablotna et al. (14) also recently reported that
there is essentially no difference between the inhibitory poten-
* This work was funded in part by a grant from the Australian
Research Council (ARC) and Hexima Ltd. The Institute of Molecular
Bioscience is a Special Research Centre of the ARC. This work was also
supported in part by a grant from Bayerischer Habilitationsfo¨rderpreis
(to U. C. M.). The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org)
contains supplemental text, Tables S1 and S2, and additional Refs. 1–5.
¶ An ARC postdoctoral fellow.
** An ARC Senior Fellow. To whom correspondence should be ad-
dressed. Tel.: 61-7-3346-2019; Fax: 61-7-3346-2101; E-mail: d.craik@
imb.uq.edu.au.
1 The abbreviations used are: SFTI-1, sunflower trypsin inhibitor-1;
BB, Bowman-Birk; DQF-COSY, double quantum filtered two-dimen-
sional correlation spectroscopy; E.COSY, exclusive COSY; LC-MS, liq-
uid chromatography mass spectrometry; NOE, nuclear Overhauser ef-
fect, also used for NOESY cross-peak; NOESY, two-dimensional NOE
spectroscopy; TOCSY, two-dimensional total correlation spectroscopy;
WATERGATE, water suppression by gradient-tailored excitation;
r.m.s.d., root mean square deviation.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 278, No. 24, Issue of June 13, pp. 21782–21789, 2003
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org21782
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
cies of cyclic SFTI-1 and this particular acyclic derivative.
Thus, it would appear that structural conservation of the reac-
tive loop of SFTI-1[1,14], rather than the cyclic backbone, is
essential for potency and that a slight disordering of the open
termini in the non-reactive loop of SFTI-1[1,14] does not sig-
nificantly reduce binding efficiency to trypsin. Although the
role of cyclization is not certain, it has been suggested that the
cyclic backbone of native SFTI-1 possibly evolved to protect it
against degradation by proteases to allow SFTI-1 to function
over an extended in vivo lifetime (11). Understanding the
mechanism of cyclization for SFTI-1 may therefore have poten-
tial applications in the pharmaceutical industry and for the
design of improved peptidic drugs.
Nothing is known so far about the cyclization mechanism for
SFTI-1 in planta, and there are no data describing enzymes
with the specificity necessary to perform this task. Here we
describe an in vitro enzymatic mechanism for the cyclization of
a linear precursor of SFTI-1, SFTI-1[6,5] (Fig. 1), that is open
at the scissile bond, i.e. the bond that would normally be
cleaved in homologous substrates. Although this mechanism,
based on the reversible equilibrium between species containing
an intact and a cleaved peptide bond, is generally applicable to
many serine proteinase inhibitors, SFTI-1 is the first example
of an inhibitor in which the peptide bond resynthesis results in
a backbone cyclic peptide. The gene sequence of the putative
precursor protein of SFTI-1 is unknown, and the demonstra-
tion of enzymatic cyclization of a linear analogue of SFTI-1
potentially provides insight into a theoretically possible in vivo
precursor.
In the current study we have gained a structural insight into
five conformers/isomers of this putative acyclic precursor and
have determined full three-dimensional structures for two of
the conformers, which we compare with the structure of
SFTI-1. In addition, anti-trypsin activity assays were carried
out for SFTI-1[6,5], and the products of a 1:1 reaction mixture
of trypsin and SFTI-1[6,5] have been analyzed. The results
have provided an insight into potential mechanisms of cycliza-
tion of SFTI-1 in vitro and in vivo.
EXPERIMENTAL PROCEDURES
Solid-phase Synthesis of Acyclic SFTI-1[6,5]—The solid phase syn-
thesis of SFTI-1[6,5] was carried out as described for another acyclic
SFTI-1 variant (11) using standard Fmoc (N-(9-fluorenyl)methoxycar-
bonyl) chemistry. The peptide was air-oxidized in 0.1 M of ammonium
bicarbonate solution, pH 8.0, for 12 to 24 h and purified by reversed-
phase high performance liquid chromatography using a conventional
C18 column and a water/acetonitrile/trifluoroacetic acid elution system.
Electrospray ionization mass spectrometry verified the mass of SFTI-
1[6,5] with an m/z value of 766.3 for the doubly charged peak.
NMR Spectroscopy—Samples prepared for NMR spectroscopy con-
tained 2 mM SFTI-1[6,5] in 20 mM sodium phosphate (H2O/D2O,
90/10%, v/v) at pH 4.5. One-dimensional 1H-NMR spectra recorded over
the temperature range 280–310 K revealed that the dispersion of peaks
was optimal at 286 K. Homonuclear two-dimensional 1H spectra were
recorded at 286 and 298 K on a Bruker DMX750 spectrometer. NOESY
and TOCSY spectra used a WATERGATE scheme (16) for water sup-
pression. The mixing times for the NOESY spectra were 200 and 300
ms, and the mixing time for the MLEV17 sequence (17) was 80 ms.
Water suppression in the DQF-COSY experiment was achieved using
selective low power irradiation of the water resonance during a relax-
ation delay of 1.3 s. 16,384 data points were collected for one-dimen-
sional spectra, and 4,096 data points in the t2 and 512 increments in the
t1 dimension were collected for two-dimensional experiments. NOESY,
TOCSY, and E.COSY spectra were recorded in D2O at 286 K. Slowly
exchanging amide protons were identified by recording a series of
one-dimensional spectra and two-dimensional TOCSY spectra at 286 K
over a period of 12 h on a sample immediately after dissolution in
99.996% D2O. A sequence-specific resonance assignment was per-
formed by standard methods (18). Cis proline residues were identified
by strong H(i)/Pro-H(i1) NOE signals in the NOESY spectrum,
whereas a trans conformation was evidenced by unambiguous H(i)/
Pro-H(i1) NOE signals and the absence of H(i)/Pro-H(i1) connec-
tivities (18). 3JNH coupling constants were obtained from a high reso-
lution one-dimensional spectrum and from line-shape analysis of the
anti-phase cross-signal splitting in a high digital resolution DQF-COSY
spectrum using a Lorentzian function for peak fitting. The 1-angles for
side-chain rotamers were obtained from line-shape analysis of H–H
couplings in an E.COSY spectrum together with NOE intensity pat-
terns between resolved HN–H protons. Secondary chemical shifts were
obtained using published random coil values (19), and specific correc-
tions for residues preceding a proline (19) were taken into account.
Structure Calculations—Distance constraints were derived from the
intensities of cross-peak signals from NOESY spectra at 286 K recorded
with a mixing time of 200 ms. The spectrum at 298 K was used to
resolve ambiguities due to spectral overlap. Distance restraints were
divided into three groups according to the relative NOESY cross-peak
intensities: strong, upper distance limit of 2.7 Å; medium, upper dis-
tance limit of 3.5 Å; weak, upper distance limit of 5.0 Å. All structures
were calculated using X-PLOR 3.851 (20) with a modified ab initio
simulated annealing protocol (21). The structure calculation strategy
was based on a three-stage simulated annealing protocol (22, 23). For
details see the Supplementary Material. An iterative approach using
several rounds of structure calculations with subsequent distance anal-
ysis was used to solve ambiguities in NOE cross-peak assignments.
Dihedral angle constraints were introduced in the later rounds of struc-
ture calculations. Distance constraints for hydrogen bonds were gener-
ated based on deuterium exchange data and by examination of struc-
ture families calculated without hydrogen-bond constraints. The 20
structures with lowest overall energies from the final 50 structures
were retained for further analysis. Structures were visualized using the
program MOLMOL (24) and analyzed with PROCHECK-NMR (25).
Trypsin Assays—Trypsin assays were carried out at 303 K as de-
scribed by Korsinczky et al. (11). The concentration of SFTI-1[6,5] was
determined by amino acid analysis. SFTI-1[6,5] (0–150 nM) and trypsin
(42 nM) were preincubated together for 3 h at 303 K. The reactions were
initiated by addition of substrate and monitored at 405 nm with
readings taken every 2 min with shaking between readings using a
Molecular Devices SpectraMax 250. All reactions were carried out in
duplicate, and the corresponding Ki value was determined using a
tight-binding equation (26).
Mass Spectroscopy/Monitoring of the Trypsin-dependent Interconver-
sion of SFTI-1[6,5] to SFTI-1—SFTI-1[6,5] and bovine -trypsin (Type
XIII L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated, EC
3.4.21.4) were incubated together at 303 K in a 1:1 ratio (350 nM each),
at pH 8.0, 50 mM Tris HCl, 25 mM CaCl2. 20-l aliquots were taken in
duplicate after 2 min and every 15 min for the first 2 h and every 30 min
FIG. 1. Amino acid sequences of SFTI-1, SFTI-1[6,5], and SFTI-
1[14,1] shown in one-letter amino acid code. The peptide backbone
is not continuous in SFTI-1[6,5] and SFTI-1[1,14] between S6 and K5
and D14 and G1, respectively. The disulfide bond between C3 and C11
in all molecules is indicated by a bold line.
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for the next 2 h and then every hour. The reaction was stopped by a
sudden pH drop to 1 by immediate addition of 5 l of trifluoroacetic
acid to the aliquots with vigorous shaking. The samples were subjected
to LC-MS analysis, using an electrospray Qq time of flight mass spec-
trometer (QSTAR Pulsar, Applied Biosystems, Foster City, CA) oper-
ated under positive ion detection conditions: declustering potential of 80
V, focusing potential of 250 V, declustering potential 2 of 10 V, and ion
spray sprayer level of 5000 V. Extracted ion chromatograms for the
doubly protonated SFTI-1[6,5] (m/z 766.3) and SFTI-1 (m/z 757.3) were
constructed, and the ratio of the two peaks was calculated using both
peak area and height. The integrity of the initial measurements was
determined by re-measuring the amounts of SFTI-1 and SFTI-1[6,5]
from the initial reaction aliquots 1 day after the initial readings. An
unchanged result for the two peptides proved that trifluoroacetic acid
addition did not degrade either SFTI-1 or SFTI-1[6,5] and did com-
pletely stop the trypsin reaction.
Isolation of SFTI-1 from Sunflower Seeds—Sunflower seeds (about 1
week prior to maturation) were ground with dry ice, and the mixture
was defatted with chilled petroleum spirit (10). The mixture was fil-
tered, and a water extraction was made from the dried solid phase. The
water extract was divided in two portions, and to eliminate possible
protease activity one portion was treated with trifluoroacetic acid to
drop the pH to 1. After centrifugation for 10 min at 15,000 rpm the
supernatants of both extracts were directly subjected to LC-MS analy-
sis and yielded identical results.
RESULTS
Multiple SFTI-1[6,5] Conformers/Isomers—The conforma-
tion of SFTI-1[6,5] in aqueous solution, pH 4.5, was determined
using NMR spectroscopy. The two-dimensional spectra con-
tained more signals than expected for a 14-amino acid peptide
(Fig. 2). Because the peptide was chemically pure, the addi-
tional spin systems must derive from multiple solution confor-
mations (cis/trans isomerization of the three proline residues),
or co-eluting isomers. Careful analysis showed that five con-
formers/isomers, called A1, A2, B, C1, and C2 (Fig. 3), were
present in sufficient quantities to exhibit signal sets that were
detected in both TOCSY and NOESY spectra. These five con-
formers/isomers can be viewed as three major species, A, B,
and C, two of which (A and C) split further into two conformers
each due to cis/trans isomerization of P8 or P9 in the NH2-
terminal part of the peptide. Species A and C are conformers of
SFTI-1[6,5], and species B is an isomer, with an altered D14
configuration. For consistency and for comparison with cyclic
SFTI-1, we retain the original numbering scheme, starting at
G1, but note that SFTI-1[6,5] is a linear peptide with a se-
quence from the NH2 to COOH termini of S6–I7 . . . T4–K5.
Species A, the major species of SFTI-1[6,5], exists as two
conformers (A1 and A2) (Fig. 3) evidenced by two sets of spin
systems for residues S6 to P9 that differ only in cis/trans
isomerization of P8, with the trans conformation (A2) being
more abundant. For species B all three Xaa-Pro bonds adopt a
trans conformation as for A2, but the backbone chemical shifts
are notably different from those of species A (Fig. 2). The most
striking feature that distinguishes species B from all the other
species is the presence of an iso-aspartate residue at position
14, as deduced from the clear absence of a H(i)HN(i1) se-
quential NOE, together with strong H(i)HN(i1) NOEs. Fur-
thermore, the high 3JHHN coupling constant (9 Hz) of residue
14 of species B correlates with an extended -angle of 120 
40°. This angle is easier to fulfill if the non-binding loop is
extended by the additional methylene group resulting in a
more relaxed ring structure. Species C exhibits an F12/P13 cis
orientation, and the four NH2-terminal amino acids (S6–P9)
adopt two different conformations: one with P8 and P9 both in
the trans orientation (C1), and one with P8 in the trans and P9
in the cis orientation (C2) (Fig. 3). For the NH2-terminal seg-
ment of C2, only the two proline residues could be definitively
assigned. Out of the three species, A exhibits backbone chem-
ical shifts that most closely resemble the corresponding shifts
FIG. 2. Fingerprint region of the NOESY spectrum of SFTI-
1[6,5] recorded at 750 MHz and 286 K (pH 4.5). Species A, B, and C
(in A, B, and C, respectively) exhibit three different sequential connec-
tivity patterns for the COOH-terminal residues I10–D14 through G1–
K5, respectively. Similarly, two different patterns are indicated for
residues S6–I7 of the NH2-terminal segments ct and tt. For P8–P9 a
third signal set (ct) could be assigned in the aliphatic region of the
spectra (not shown). The sequential connectivity pattern is only broken
at P8, P9, and P13. The sequential connectivities from I10 to P9 are
indicated explicitly for all three species, and the designations ct and tt
in parentheses describe the conformers of the NH2-terminal part of the
molecule (residues S6–P9).
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of native cyclic SFTI-1 (Fig. 4), and A1 exhibits the same
geometry for all three prolines as cyclic SFTI-1 (11) (Protein
Data Bank code 1JBL).
Secondary Structure of SFTI-1[6,5] Conformers/Isomers—A
summary of the secondary chemical shifts from I10 to T4 for all
three SFTI-1[6,5] species relative to those of cyclic SFTI-1 is
given in Fig. 4. Consecutive downfield shifted H resonances,
indicative of extended structure, were found for G1 to C3 of
both cyclic SFTI-1 and the SFTI-1[6,5] species A, with another
distinctive downfield shifted value for C11. Species C exhibits
consecutive upfield shifted H resonances for residues F12 to
D14, indicating helical or turn-like structure. For species B, no
indications of regular secondary structure were found. These
findings were supported by an analysis of the 3JNH coupling
constants. For species A they were 8 Hz for C3, C11, and I10,
representing residues in an extended structure. For species B
F12 and iso-D14 had coupling constants 8 Hz, and for species
C only C11 exhibited a coupling constant typical of an extended
conformation. No coupling constants 6 Hz, which are typical
of an -helix, were detected for any of the three species. Slow
exchanging amide protons were only detected for I10, F12, G1,
and R2 of species A. Further evidence for a -sheet like struc-
ture for species A was deduced by a strong H–H NOE be-
tween the two cysteine residues. In summary, evidence for
regular secondary structure could only be deduced for species
A, indicating a small anti-parallel -sheet.
Structure Calculations—Structure calculations were per-
formed for the four conformers and one isomer of SFTI-1[6,5].
Input data and structure statistics are summarized in Table I.
The structure calculations provided well-defined structures for
the two conformers of species A with a backbone r.m.s.d. for the
final 20 structures of 0.49 Å for A1 and 0.45 Å for A2 (protein
data bank codes: A1, 1O8Z; A2, 1O8Y).
Species A exhibits a hairpin structure that is similar for both
conformations (A1/A2) and closely resembles the corresponding
region of cyclic wild-type SFTI-1, i.e. a short double-stranded
anti-parallel -sheet connected by the disulfide bridge and
stabilized by hydrogen bonds (Fig. 5). The difference between
the two conformations is the cis/trans isomerization of P8. The
I7–P8 bond shows a cis orientation in the minor conformer A1,
essentially maintaining the binding loop orientation, even
though the backbone is open between residues K5 and S6. In
the major conformer A2, P8 is in a trans configuration, giving
the binding loop an extended conformation (Fig. 5).
The structure calculations for species B and the two confor-
mations of species C did not result in convergent structures due
to limited NOE information. However, it could be deduced,
from chemical shift data and the absence of certain character-
istic NOEs, that the small -sheet found for both conformations
of species A is not present in species B and C.
Trypsin Catalyzed Cyclization of SFTI-1[6,5]—Although
trypsin is normally used to facilitate proteolysis, i.e. peptide
bond cleavage, this equilibrium reaction is in principle revers-
ible, and we were interested to see if presentation of an acyclic
precursor species would result in cyclization. Therefore, a 1:1
mixture of SFTI-1[6,5] with bovine -trypsin was incubated at
303 K (pH 8). Aliquots of the reaction mixture were taken over
a 24-h period, and LC-MS analysis confirmed that cyclic SFTI-1
was indeed produced. The ratio of the intact and cleaved form
of SFTI-1 was determined by quantitative analysis of the peaks
with masses corresponding to SFTI-1[6,5] and cyclic SFTI-1
(Fig. 6). After 2 min of reaction time, cyclic SFTI-1 could be
detected. A steady state was reached after 130 min and
resulted in 90% SFTI-1 to 10% SFTI-1[6,5] (Fig. 6). Coelution
experiments with added synthetic SFTI-1 and SFTI-1[6,5] con-
firmed that the resulting molecules are indeed the cleaved and
intact inhibitor.
The above procedure was repeated starting with cyclic
SFTI-1 under the same conditions. After a reaction time of 2
FIG. 3. Schematic summary of the identified species (A–C) of
SFTI-1[6,5]. The top panel shows SFTI-1[6,5] in one-letter amino acid
code, and the disulfide bond between residues C3 and C11 is repre-
sented as a bold line. The double line between residues P9 and I10
indicates the break between the NH2- and COOH-terminal segments of
signal sets. The right lower panel shows residues K5–I10 of species A,
B, and C (COOH-terminal signal sets) highlighting some key residues.
The segments ct, tt, and tc (NH2-terminal signal sets), containing res-
idues S6–P9, are shown in the left lower panel. Dotted lines indicate the
sequential connections between I10 and P9 of species A, B, and C with
the corresponding segments ct, tt, and tc to form the five different
conformers/isomers, including the sub-species of A (A1 and A2) and C
(C1 and C2).
FIG. 4. H secondary chemical shifts of cyclic SFTI-1 in 20%
TFE (white) (pH 4.5) recorded at 750 MHz and 273 K, species A of
SFTI-1[6,5] in water (black), species B of SFTI-1[6,5] in water
(hatched lines sloping down to the left) and species C of SFTI-
1[6,5] in water (hatched lines sloping down to the right) (pH 4.5)
recorded at 750 MHz and 286 K. K5 is omitted, because it is the open
COOH-terminal residue in SFTI-1[6,5], and therefore, a comparison to
the closed K5 residue of cyclic SFTI-1 is not meaningful.
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h, cleaved SFTI-1[6,5] in a yield of about 7% was recovered.
Therefore, a ratio of cyclic SFTI-1 to SFTI-1[6,5] of 9:1 was
reached regardless of whether the reaction was initiated with
SFTI-1 or SFTI-1[6,5].
Isolation and Verification of the Cyclic Nature of SFTI-1 in
Sunflower Seeds—The previously reported isolation procedure
of SFTI-1 from sunflower seeds (10, 27) involved the incubation
of SFTI-1 on a trypsin affinity column for up to 2 h. Given that
SFTI-1[6,5] can be 90% converted into the cyclic form when
incubated with trypsin in a similar time frame and that Luck-
ett et al. (10) reported a ratio of9:1 of intact to cleaved SFTI-1
after trypsin affinity column purification, the question was
raised as to whether the peptide is actually acyclic in its nat-
ural state and whether the exposure to trypsin on the affinity
column may have made it cyclic. We therefore repeated the
isolation of SFTI-1 from fresh sunflower seeds with a method
similar to that described by Luckett et al. (10) but omitted the
trypsin affinity column step. In the water extract the mass of
the doubly charged ion of cyclic SFTI-1 (M  757.32) was
detected, with neither the single nor doubly charged ion of
acyclic SFTI-1[6,5] being present. In a separate experiment, we
added synthetic cyclic SFTI-1 to the water extract, and subse-
quent LC-MS analysis of this mixture resulted in one sharp peak
with the correct mass for SFTI-1. This confirms unambiguously
that SFTI-1 is present naturally in cyclic form in the seed.
Trypsin Inhibition Assays—Trypsin assays were carried out
as previously described (11). SFTI-1[6,5] inhibited bovine
-trypsin with a Ki of 0.54  0.1 nM (Fig. 7), a result identical
to that for cyclic SFTI-1. Interestingly though, cyclic SFTI-
1[6,5] shows inhibitory activity with minimal incubation,
whereas SFTI-1[6,5] requires a 2- to 3-h preincubation with
trypsin to show substantial inhibitory activity, thus making
SFTI-1[6,5] a less effective inhibitor. This delay in complex
formation is further examined in the discussion section.
DISCUSSION
Three-dimensional Structure of SFTI-1[6,5]—In this report
we have synthesized an acyclic permutant of SFTI-1, SFTI-
1[6,5], determined the three-dimensional structures of two of
its solution conformers and obtained valuable structural infor-
mation on three other conformers/isomers. Although SFTI-
1[6,5] consists of only 14 amino acids, it exhibits substantial
structural heterogeneity caused by cis/trans isomerization of
the three proline residues and by the presence of an iso-aspar-
tate residue in one isomer.
TABLE I
Structural and energetical statistics for the conformers/isomers of SFTI-1[6,5]
Conformers/isomers
Species
A B C
A1 A2 B C1 C2
NOEs 63 73 36 47 35
-Angle restraints 3 3 2 1 1
1-Angle restraints 3 3 2 2 2
Hydrogen-bonds 4 4
Energy statistics over 20 structures
kcal/mol
Overall 30.05  0.17 29.91  0.03 29.93  0.05 32.86  0.92 34.09  1.12
Bond length 1.07  0.01 1.05  0.005 1.05  0.008 1.25  0.11 1.29  0.08
Bond angles 26.22  0.10 26.12  0.03 26.16  0.07 27.74  0.50 28.86  0.86
Improper 1.88  0.01 1.89  0.002 1.89  0.004 1.99  0.13 2.08  0.16
van der Waals 0.84  0.04 0.84  0.02 0.83  0.03 1.54  0.35 1.64  0.31
NOEs 0.04  0.06 0.005  0.01 0.003  0.01 0.33  0.32 0.23  0.23
Angle restraints 0.0  0.0 0.00001  0.00006 0.000003  0.00001 0.0005  0.0021 0.00004  0.0001
Atomic RMSDs values from the average structures
Å
Overall
Backbone 0.492 0.450 2.324 2.104 2.288
Heavy atoms 1.206 1.067 3.462 3.152 3.089
C11–3
Backbone 0.134 0.093 1.157 1.002 0.916
Heavy atoms 0.940 0.832 2.361 2.077 1.906
FIG. 5. Ensemble of 20 structures of the most abundant species
(species A) of SFTI-1[6,5]. Conformer A1 (cis I7–P8 conformation,
pdb code 1O8Z) and conformer A2 (trans I7–P8 conformation, pdb code
1O8Y) superimposed over the backbone heavy atoms of all residues.
The backbone of the conformers A1 and A2 are colored purple and pink,
respectively, and the disulfide bond between C3 and C11 is colored
yellow. The P1–P1 site occurs at the break in the backbone between
residues K5 and S6.
FIG. 6. Trypsin catalyzed cyclization of SFTI-1[6,5]. Formation
of cyclic SFTI-1 over time is represented by a solid line and filled circles
with error bars. Conversion of SFTI-1[6,5] over time is represented by a
dotted line and filled squares with error bars.
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The major species present in solution (A) exhibits a -hairpin
structure from C11 to C3 similar to wild-type cyclic SFTI-1 and
forms two conformers (A1 and A2) that differ only by a cis/trans
isomerization about the I7/P8 peptide bond. The three-dimen-
sional structure of the cis conformer A1 of SFTI-1[6,5] closely
resembles the structure of cyclic SFTI-1. The C atom r.m.s.d.
value between the solution structures of A1 and SFTI-1 (1JBL) is
0.98 Å and that between A1 and the crystal structure of SFTI-1
in complex with trypsin (1SFI) is 1.21 Å, indicating that, al-
though the backbone is open between residues K5 and S6, the
binding loop orientation is essentially maintained (Fig. 5).
The second most abundant species (B) features backbone
chemical shifts that differ notably from those of species A and
also from those of cyclic SFTI-1. In this species all three Xaa-
Pro peptide bonds are in a trans orientation and there is an
iso-aspartate residue at position 14. The number of structural
restraints for species B, however, was not sufficient to result in
a family of converging structures, same as for species C.
Trypsin-catalyzed Cyclization of SFTI-1[6,5]—In addition to
defining the conformational properties of SFTI-1[6,5] we exam-
ined its reactivity. We have shown that the proteolytic enzyme
trypsin is able to resynthesize the peptide bond between the
P1/P1 residues (nomenclature according to Ref. 28) and con-
sequently cyclizes the linear precursor SFTI-1[6,5] to form
native cyclic SFTI-1. The cyclization reaction occurs very effi-
ciently: a stable ratio of more than 9:1 of cyclic SFTI-1 to acyclic
SFTI-1[6,5] is reached within 2 h. Resynthesis of a peptide
bond between P1/P1 residues upon interaction with a suitable
proteinase has previously been demonstrated for various pro-
teinase inhibitors (29, 30), but the resynthesis of this bond in
SFTI-1[6,5] is unique because it leads to a cyclic peptide chain
rather than ligation of two chains, as is the case for other
classic inhibitors. No matter which form of the inhibitor was
incubated with enzyme, after a sufficient reaction time over 90%
of cyclic inhibitor was present. This result proves that cyclic
SFTI-1 and the cleavage product SFTI-1[6,5] are interconvertible
and that the enzyme-inhibitor complex C is the same, no matter
whether it was made from the proteinase E and the virgin inhib-
itor I or E, and the modified inhibitor I* (29), in accordance to the
equilibrium nature of the canonical mechanism of inhibition
given by Finkenstadt and Laskowski (8),
E  IL|;
kon
koff
CL|;
koff*
kon*
E  I*
REACTION 1
Kinetically controlled dissociations of other proteinase-inhibi-
tor complexes generally yield ratios, [I]/[I*], of virgin to modi-
fied inhibitor of at least 9, which is in accordance with the ratio
we have found for the SFTI-1/SFTI-1[6,5] system. This high
ratio, together with the fast reaction, provides an efficient
mechanism for in vitro cyclization of SFTI-1.
From the crystal structure of SFTI-1 in complex with trypsin
it is known that the peptide bond between K5 and S6 is intact
in the inhibitory complex (10). Our experimental results show
that this inhibitory complex can also be formed using SFTI-
1[6,5] instead of SFTI-1, in accordance with Reaction 1. Con-
sequently, both peptides have identical inhibition constants,
and SFTI-1[6,5] itself is a strong trypsin inhibitor. However,
complex formation using SFTI-1[6,5] is significantly slower
than complex formation using cyclic SFTI-1, mostly because
peptide bond formation has to occur as a preceding step when
complex formation starts with SFTI-1[6,5], in accordance with
an extended version of Reaction 1,
E  IºLºCºX*ºL*ºE  I*
REACTION 2
where L and L* are loose complexes, and X* is an additional
intermediate (31). This is evidenced by the similar time frame
for the trypsin-catalyzed cyclization of SFTI-1[6,5] and the
appearance of inhibitory activity of SFTI-1[6,5].
In the case of SFTI-1[6,5] as I* an even more complex equi-
librium is present, contributing further to its slower associa-
tion rate, because it is not a structurally homogeneous com-
pound but a mixture of conformers/isomers that are in mutual
equilibrium. A consideration of geometric factors suggests that
the orientation of the S6 to I10 binding loop arm, in particular
the cis conformation of P8 in the P3 position, is a prerequisite
for an efficient interaction of SFTI-1[6,5] with trypsin. Because
our studies show that none of the multiple SFTI-1[6,5] con-
formers/isomers are present at more than 40% in solution,
there must be equilibration between the isomers/conformers to
produce 90% of cyclic SFTI-1 after reaction with trypsin,
namely cis/trans isomerization of the proline residues. There
has to be equilibration between the iso-D14 and D14 isomers as
well, because about 30% of all molecules contain the iso-aspar-
tate residue. It appears that, at the beginning of the incubation
with trypsin, only a fraction of all SFTI-1[6,5] molecules pres-
ent in solution, those adopting the A1 conformation, fulfills the
requirements to fit into the active site pocket of the proteinase.
Mimicry of Larger Bowman-Birk Inhibitors—Like all canon-
ical serine proteinase inhibitors, proteins of the BB inhibitor
family interact with the enzymes they inhibit via an exposed
surface loop that adopts a canonical proteinase inhibitory con-
formation. A particular feature of full-length BB inhibitor pro-
teins is that the interacting loop is stabilized by a well-defined
disulfide-linked -sheet region. For small nonapeptides com-
prising the 9-amino acid active site loop and the disulfide
bridge, this -sheet is shortened and the reduced stabilization
is accompanied by poorer inhibitory activities (32). These small
synthetic peptide mimics of BB inhibitor proteins are able to
bind to and inhibit target proteinases, but when cleaved at the
active site peptide bond, they are incapable of being resynthe-
sized by the proteinase (32, 33). NMR studies on such nonapep-
tides did not result in stable structures (34). In contrast to
these small peptides, the -sheet structure is intact in SFTI-1
and in both species A conformers of SFTI-1[6,5], even if the
active site peptide bond is hydrolyzed. This stabilization is
sufficient to make SFTI-1[6,5] amenable to resynthesis of the
active site peptide bond. Thus, the intact -sheet structure
seems to be another prerequisite for the pre-orientation of the
two “arms” of the cleaved inhibitory loop for an efficient inter-
FIG. 7. Inhibition of bovine -trypsin by SFTI-1[6,5]. Trypsin
activation was assayed using the substrate N-benzoyl-L-arginine-p-
nitroanilide, as described under “Experimental Procedures.”
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action with the proteinase. The importance of flanking residues
for the short -sheet is also supported by the fact that a syn-
thetic undecapeptide derived from a combinatorial peptide li-
brary screening also exhibits a very stable -hairpin structure
across the active site loop (35). One goal of studies on BB
inhibitors has been a determination of the minimal require-
ments necessary to retain the proteinase inhibitory activity of
full-length inhibitors (32, 33). All investigations so far have
kept the canonical loop intact, and variations have been made
in specific side chains. Here we report that it is not necessary
to keep the P1/P1 site intact to maintain activity, as long as
the scaffold of the loop, stabilized by the -hairpin loop located
opposite to the binding loop is maintained.
In Vivo Synthesis of Cyclic SFTI-1—Little is known about
the in vivo cyclization mechanisms of naturally occurring cyclic
peptides/proteins, and it is likely that different cyclization
mechanisms might apply to different peptides. Here we have
shown that the cyclic nature of SFTI-1 is not an artifact of the
previously used purification scheme (10) and that SFTI-1 oc-
curs naturally in the cyclic form in the seed. The possibility
that a small linear precursor (e.g. SFTI-1[6,5]) is cyclized via a
reaction with native proteinases present in the seed constitutes
one hypothesis for the in vivo synthesis of cyclic SFTI-1. Vari-
ous serine proteinases that might be suitable for this task are
indeed present in plant seeds (36–40). However, the gene en-
coding SFTI-1 is not known and, hence, nor is the location of
the native termini of a linear precursor peptide. Analysis of the
genes encoding the cyclic peptide RTD-1 from Macaca mulatta
has shown that more complicated cyclization mechanisms are
conceivable and that the precursor is not necessarily one con-
tinuous peptide chain (41).
A second hypothesis for the synthesis of cyclic SFTI-1 can be
derived from the fact that all known cyclic mini-proteins from
plants appear to be derived from longer precursor proteins (1),
and, therefore, both cleavage and cyclization steps seem to be
involved in their synthesis. The majority of BB inhibitors from
dicot plants comprise 60–90 amino acid residues and have a
symmetrical double-headed structure with independent inhib-
itory activity, either against trypsin or chymotrypsin (32). In
contrast, SFTI-1 consists of only 14 amino acid residues and
has only one inhibitory loop. Its small size leads to the sugges-
tion that SFTI-1 is possibly derived from a “normal size” BB
inhibitor as a result of peptide bond cleavage followed by a
transpeptidation reaction or a peptide bond double cleavage
followed by a ligation reaction. A likely location for the joined
ends of cyclic SFTI-1 is the D14–G1 position within the non-
binding loop (Fig. 8). The detection of an iso-aspartic acid
residue in position 14 of one of the structural species of SFTI-
1[6,5] is an indication of the high reactivity of this functional
residue and supports the possibility of participation of this
residue in a transpeptidation reaction. However, up to now, no
putative precursor protein of the BB inhibitor family is known
with D and G or alternatively N and G in the relevant
positions.
From the existence of the iso-Asp residue a third alternative
suggestion for in vivo cyclization of SFTI-1 is conceivable, start-
ing from the putative precursor SFTI-1[1,14] (Fig. 8). In gen-
eral, peptide bonds are subject to both acid and base hydrolysis.
Most peptide bonds are stable except those in Asp-Xaa se-
quences, with cleavage being particularly rapid at D–G and
D–P bonds due to a reduced energy barrier (42). Because pep-
tide bond hydrolysis/synthesis is an equilibrium reaction, it can
theoretically occur in both directions. For linear peptides the
reversal reaction is highly unlikely due to separation of the
reaction products. However, formation of the D-G bond in
the case of a linear SFTI-1 precursor open between G1 and D14
leading to cyclic SFTI-1 is not as difficult, because both termini
are in close proximity due to the disulfide bond and the contin-
uous sequence of the putative precursor. Because the side-
chain carbonyl group of D14 is involved in a hydrogen bond
with the amide proton of R2, it is available for a nucleophilic
attack of the amide nitrogen of G1 for succinimide formation.
Hydrolysis on either side of the succinimide nitrogen atom
results in an D or iso-D residue within the peptide chain. A
feasible mechanism for cyclization of SFTI-1 from SFTI-1[1,14]
is the formation of a cyclic anhydride within D14, which would
lead after nucleophilic attack of G1 to a peptide bond between
D14 and G1. However, this reaction does not seem to occur
spontaneously as no cyclic product was detected in our inves-
tigation of this putative precursor of SFTI-1 (11) indicating
that a catalytic enzyme might be necessary. Alternatively, a
COOH-terminal N instead of D residue within a putative pre-
cursor peptide could form an intra-residual succinimide that
might more readily be attacked by the NH2-terminal G1 than
the cyclic anhydride of aspartate. Subsequent deamidation of
the asparagine residue would lead to the formation of cyclic
SFTI-1 with its D–G peptide bond. Interestingly, the cyclic
inhibitor MCoTI-II from Momordica cochinchinensis exhibits
also an D–G peptide bond that gives rise to two isomers of
MCoTI-II (9).
CONCLUSIONS
We have shown in the current study that SFTI-1[6,5], an
acyclic permutant of the cyclic peptide SFTI-1, adopts several
equilibrating conformers/isomers in solution, one of which is
very similar to the cyclic native peptide. Furthermore, treat-
ment of this acyclic permutant with trypsin results in cycliza-
tion to produce SFTI-1. This process represents a potential
biosynthetic pathway for SFTI-1, in addition to being an effi-
cient in vitro reaction for backbone cyclization. Homology with
larger BB inhibitors suggests, however, that a more likely
possibility would involve processing near residues D14–G1,
opposite to the reactive site (Fig. 8). Further studies are under
way to determine the biosynthetic origin of this potent cyclic
inhibitor.
FIG. 8. Possible mechanisms for the synthesis of cyclic SFTI-1
in vivo. Stick representation of the solution structures of SFTI-1[6,5]
conformer A1 with the cis I7-P8 bond (1O8Z), SFTI-1[6,5] sub-species
A2 with the trans I7-P8 bond (1O8Y), the mean structure of Bowman-
Birk inhibitor from Soybean (1BBI) (43), SFTI-1[1,14] (1JBN (11)), and
cyclic SFTI-1 (1JBL (11)) are depicted. The circle around the trypsin
cleavage product SFTI-1[6,5] represents the region where cyclization
does occur in vitro to form SFTI-1 (first hypothesis). The circle on 1BBI
represents the region where putative cyclization may occur to form the
smaller protein SFTI-1 (second hypothesis), and the circle on the puta-
tive gene product SFTI-1[1,14] (or alternatively a peptide with a COOH-
terminal N instead of D) represents the region where cyclization may
occur to form SFTI-1 (third hypothesis).
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Supplementary Material
Sequential Assignment of SFTI-1[6,5]
A careful analysis of the homonuclear 2D spectra shows that five conformers/isomers
are present in sufficient quantities to exhibit signal sets that can be detected in both TOCSY
and NOESY spectra.  For residues I10 to K5 in the COOH-terminal two-thirds of the
molecule complete assignments can be made for three independent signal sets, which belong
to three different SFTI-1[6,5] species, here named A, B, and C, roughly in order of decreasing
abundance as judged from the NMR spectra (Figure 2 of the publication).  For residues S6 to
P9 in the NH2-terminal part of the molecule three independent signal sets (called ct, tt and tc)
can also be identified, which correspond to different conformations of residues P8 and P9
(Figure 3 of the publication).  The sequential cross peaks between residues P9 and I10 (Figure
2) allow several possible sequential connections between these two residues and thus between
the NH2- and COOH-terminal signal sets, resulting in an overall identification of the five
different conformers/isomers shown diagrammatically in Figure 3 of the publication.  These
five conformers/isomers can be viewed as three major species, A, B and C, two of which (A
and C) split further into two conformers each due to cis/trans isomerisation of P8 or P9 in the
NH2-terminal part of the peptide.  As described in the publication, species A and C are
conformers of SFTI-1[6,5], and species B is an isomer, with an altered D14 configuration.
The chemical shifts at 286 K for the COOH-terminal fragments A, B, and C (Table
S1) as well as for the NH2-terminal segments tc, tt, and ct (Table S2) are given below.
Structure Calculations
The structure calculation strategy was based on a three-stage simulated annealing
protocol (1) and included floating assignments of prochiral groups (2), a modified
conformational database potential term (3,4), and a reduced contribution for non-bonded
interactions (5) for part of the calculation to increase efficiency. The option "SUM" for the
NOE averaging function in XPLOR was used so that explicit pseudo-atom correction for
unresolved methyl or methylene proton resonances was not necessary. The conformational
search phase (80 ps of molecular dynamics at 2000 K) was followed by a refinement in which
the system was cooled to 1000 K within 60 ps, accompanied by increasing of the force
constant for non-bonded interactions and angle energy constants for the diastereospecifically
unassigned groups to their final values.  While applying these high force constants the system
was cooled from 1000 to 100 K over 30 ps.  To approach the energy minimum, 1200 steps of
energy minimisation were performed, the final 1000 steps without the conformational
database potential.
Table S1
Chemical shifts at 286 K for the COOH-terminal fragments A, B, and C of SFTI-1[6,5],
(comprising residues I10-K5)
Res. HN Hα* Hβ* Hγ* others
Cys3A 8.64 5.48 3.06, 2.97
Thr4A 8.80 4.40 4.32 1.30
Lys5A 8.22 4.22 1.83, 1.73 1.40 Hε=7.54,
Hε*=2.96,
Hδ*=1.65
Arg2A 7.87 4.40 1.93, 1.89 1.58 Hε=7.42,
Hδ*=3.16
Gly1A 8.43 4.23, 3.78
Asp14A 8.02 4.53 3.12, 2.82
Pro13A 4.38 2.40, 1.97 2.16, 2.06 Hδ1=4.02,
Hδ2=3.96
Cys11A 8.34 5.15 2.89
Ile10A 8.19 4.05 1.70 1.44, 1.03,
0.63
Hδ*=0.80
Phe12A 8.77 4.83 3.34, 3.00 Hδ*=7.27,
Hε*=7.22
Res. HN Hα* Hβ* Hγ* others
Ile10B 8.18 3.94 1.68 1.40, 1.07,
0.65
Hδ*=0.81
Cys11B 8.30 4.55 2.97, 2.89
Phe12B 8.84 4.95 3.12, 2.88 Hδ*=7.27
Pro13B 4.42 2.28, 1.89 2.02 Hδ1=3.83,
Hδ2=3.61
iso-Asp14B 8.70 4.71 2.89, 2.81
Gly1B 8.41 4.22, 3.78
Arg2B 8.48 4.40 1.81, 1.75 1.67, 1.60 Hε=7.18,
Hδ*=3.17
Cys3B 8.79 4.85 3.20, 2.79
Thr4B 8.29 4.32 4.20 1.18
Lys5B 8.26 4.21 1.83, 1.72 1.39 Hε*=2.96,
Hδ*=1.65
Res. HN Hα* Hβ* Hγ* others
Ile10C 8.21 4.12 1.79 1.48, 1.15 Hδ*=0.85
Pro13C 3.93 1.81, 1.66 1.73 Hδ1=3.47,
Hδ2=3.36
Cys11C 8.49 4.62 3.11, 2.82
Asp14C 8.65 4.50 2.83, 2.73
Gly1C 8.39 4.08, 3.78
Arg2C 7.87 4.41 1.83, 1.71 1.51 Hδ*=3.13
Cys3C 8.50 4.71 3.24, 2.98
Thr4C 8.31 4.32 4.19 1.19
Lys5C 8.26 4.21 1.84, 1.72 1.39 Hε*=2.97,
Hδ*=1.64
Phe12C 8.31 4.61 2.97 Hε*=7.36,
Hζ=7.31,
Hδ*=7.22
Table S2
Chemical shifts at 286 K for the NH2-terminal fragments ct, tt, and tc of SFTI-1[6,5],
comprising residues S6-P9.
ct
Res. HN Hα* Hβ* Hγ* others
Ser6 4.07 3.88
Ile7 8.57 4.11 1.76 1.45, 1.03 Hδ*=0.84
Pro8 4.98 2.47, 2.07 1.92, 1.83 Hδ1=3.59,
Hδ2=3.52
Pro9 4.42 2.29, 1.85 2.03 Hδ1=3.75,
Hδ2=3.65
tt
Res. HN Hα* Hβ* Hγ* others
Ser6 4.14 3.95, 3.88
Ile7 8.64 4.52 1.84 1.48, 1.16,
0.96
Hδ*=0.85
Pro8 4.66 2.33, 1.85 2.05, 1.98 Hδ1=3.91,
Hδ2=3.68
Pro9 4.38 2.23, 1.80 1.96 Hδ1=3.77,
Hδ2=3.59
tc
Res. HN HA* HB* HG* others
Pro8 3.70 1.59 1.66 Hδ1=3.41,
Hδ2=3.29
Pro9 4.44 2.26, 1.90 2.00 Hδ1=3.77,
Hδ2=3.63
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